# EDGAR Filing Document

**Accession Number:** 0001907108
**File Stem:** 0001193125-25-297231
**Filing Date:** 2025-11
**Character Count:** 2412
**Document Hash:** da54c5e56fa3f1de4f6f745e6185010c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-297231.hdr.sgml**: 20260407

**ACCESSION NUMBER**: 0001193125-25-297231

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251125

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lexeo Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001907108
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 854012572
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 345 PARK AVENUE SOUTH
- **STREET 2:** FLOOR 6
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** (212) 547-9879

**MAIL ADDRESS:**
- **STREET 1:** 345 PARK AVENUE SOUTH
- **STREET 2:** FLOOR 6
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010

Lexeo Therapeutics, Inc.

345 Park Avenue South, Floor 6

New York, New York 10010

November 25, 2025

**VIA EDGAR** 

U.S. Securities and Exchange Commission

Office of Life Sciences

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-3720

---

| | |
|:---|:---|
| **Re:** | **Lexeo Therapeutics, Inc.**  |

---

**Registration Statement on Form S-3** 

**File No. 333-291269** 

**Acceleration Request** 

**Requested Date: November 26, 2025** 

**Requested Time: 4:00 P.M. Eastern Time** 

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Lexeo Therapeutics, Inc. (the "**Company**") hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-291269) (the "**Registration Statement**") be declared effective at the "Requested Date" and "Requested Time" set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Megan J. Baier at (212) 497-7736.

---

| |
|:---|
|  Sincerely, |
|  LEXEO THERAPEUTICS, INC. |
|  /s/ Jenny R. Robertson |
|  Jenny R. Robertson |
|  Chief Legal Officer |

---

cc: R. Nolan Townsend

**Lexeo Therapeutics, Inc.** 

Megan J. Baier

David G. Sharon

**Wilson Sonsini Goodrich & Rosati, P.C.**